Roche to fast-track weight loss drugs

By Reuters

Jul 30, 2024 12:04 am

SWISS drugmaker Roche plans to accelerate the development of its anti-obesity drugs to challenge rivals like Eli Lilly and Novo Nordisk in the booming market, the Financial Times reported on Monday.

Roche is among a growing number of would-be rivals to Novo and Eli Lilly, whose weight-loss injections have been in feverish demand, with experts boosting their sales forecasts for such treatments to as much as $150 billion by the early 2030s.

Already have an active account? Log in here to continue reading.
Or
Subscribe to the Premium Subscription plan to access this subscriber-exclusive article.

Related Articles

China woes dent business sentiment

Why Fed rate cuts matter to world markets

Italy backs tariffs on Chinese electric cars

TikTok's US future hangs in the balance at federal court

China's economy softens in August

Boeing workers' strike could be extended

Bank of Canada open to more rate cuts